Welcome to our dedicated page for Concord Medical news (Ticker: CCM), a resource for investors and traders seeking the latest updates and insights on Concord Medical stock.
Concord Medical (CCM) provides investors and healthcare professionals with centralized access to critical updates about its oncology services and network operations. This resource aggregates official press releases and verified news covering strategic developments in cancer care innovation.
Users gain timely insights into earnings announcements, technology adoption (including radiotherapy advancements), and partnership developments across China's healthcare sector. The collection serves as a definitive source for tracking clinical protocol implementations, diagnostic imaging innovations, and network expansion initiatives.
All content undergoes verification to ensure alignment with Concord Medical's focus areas: precision radiotherapy treatments, multidisciplinary care models, and medical equipment distribution. Bookmark this page for efficient monitoring of CCM's operational milestones and industry leadership in oncology services.
Concord Medical (NYSE: CCM) announced plans to change the ADS Ratio of its American depositary shares (ADS) from 1 ADS representing 3 Class A ordinary shares to 1 ADS representing 30 Class A ordinary shares. This change is expected to be effective on July 30, 2024. The ADS holders must surrender and exchange every 10 existing ADSs for 1 new ADS. JPMorgan Chase Bank will manage the exchange process. No fractional new ADSs will be issued; fractional entitlements will be sold, and proceeds will be distributed to ADS holders. This ratio change is anticipated to proportionally increase the ADS trading price, but cannot guarantee it will be ten times the previous trading price.
Concord Medical Services Holdings Limited (NYSE: CCM) announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2022. This report is accessible on both Concord Medical's investor relations website and the SEC's website. Concord Medical specializes in oncology services, providing a full cycle of cancer diagnosis, treatment, education, and prevention via a network of radiotherapy and diagnostic imaging centers in China. The company emphasizes the deployment of advanced technology, including proton therapy systems, to enhance cancer care quality and accessibility. Shareholders can request a hard copy of the report free of charge.
Concord Medical Services Holdings Limited (NYSE: CCM) will hold its 2022 annual general meeting of shareholders on December 30, 2022, at 10:00 a.m. Beijing Time. The meeting will take place at the Global Trade Center in Beijing, and the shareholder record date is November 30, 2022. No proposals will be submitted for approval, as the meeting aims to facilitate discussions between shareholders and management. Additionally, the Company’s annual report on Form 20-F for the fiscal year ending December 31, 2021, is accessible on its investor relations website.
Concord Medical Services Holdings Limited (NYSE: CCM) successfully hosted the Second Annual Academic Meeting with MD Anderson Cancer Center on November 11-12, 2022. The event focused on 'Immuno-Oncology: Confronting the Whole Cancer Continuum,' gathering experts from China and the U.S. to discuss advancements in cancer treatment and research. Notable topics included immunotherapy for cancer prevention and emerging cellular therapies. The meeting attracted nearly 100 oncology scholars globally and demonstrated Concord Medical's commitment to enhancing international collaboration in oncology.
Concord Medical Services Holdings Limited (NYSE: CCM) announced key management changes effective September 30, 2022. Chief Financial Officer and President Yaw Kong Yap stepped down upon reaching retirement age, with Boxun Zhang appointed as his successor. Independent directors Boxun Zhang and Weibo Yin resigned for personal reasons. New independent directors Wayne Yu and Hongzhong Liu joined the Board, enhancing its expertise. The company expresses gratitude to outgoing management and directors, emphasizing the aim to continue delivering value to shareholders through its oncology services across China.
FAQ
What is the current stock price of Concord Medical (CCM)?
What is the market cap of Concord Medical (CCM)?
